Biopharmaceuticals are booming in Asia, buoyed by enhanced regulations, an influx of venture capital, a culture of innovation, and government support.
The Rise of Biopharmaceutical Manufacturing in Asia
Cover: Biopharmaceuticals are booming in Asia, buoyed by enhanced regulations, an influx of venture capital, a culture of innovation, and government support. Asian pharmaceutical manufacturing has traditionally focused on generics, but things are changing.
Lego Blocks for Chemists—The Advent of Continuous Manufacturing
Feature: Spurred by pressure from governments and consumers to curb rising drug prices, pharmaceutical manufacturers are increasingly willing to look beyond traditional batch processing to cut costs and increase efficiency. Markus Krumme, Head of Continuous Manufacturing at Novartis, shares his thoughts on one of the industry’s most dramatic innovations.
Supply Chains—Dramatic Changes Ahead
Feature: Biopharmaceutical supply chains are undergoing dramatic changes. Predominant among these is the shift away from primary care to specialty products and personalized medicine, and from large-scale production of low-value small molecules to low-volume, high-value biologics. Andy Skibo, Head of Global Biologics Operations and Engineering, MedImmune/AstraZeneca, tells us why specialty product supply chains must be managed in a different way.